What aspect does 'Safety' population primarily focus on?

The 'Safety' population primarily focuses on the actual receipt of the investigational treatment. This population includes all participants who received at least one dose of the treatment being studied, making it crucial for evaluating the safety profile of the intervention. By assessing those who have actually been treated, researchers can monitor adverse events and side effects accurately, allowing for a comprehensive understanding of the treatment's safety. This information is particularly important for regulatory authorities to ensure that the benefits outweigh the risks before the treatment can be marketed or approved for widespread use. The emphasis on the actual receipt of the therapy distinguishes the 'Safety' population from other study populations that may focus on different aspects such as efficacy or long-term outcomes.